Sort
21,281 grants matching “influenza”
Systems Biology Approaches to Viral Pathogenesis and Immunity
$1,013,435Michael G Katze · Oregon Health & Science University · U54 · FY2009 · AI
IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A
$1,013,003Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma
$1,012,736John H Sampson · Duke University · U01 · FY2018 · NS
Influenza Immunity: Protective Mechanisms Against Pandemic Respiratory Virus
$1,012,718Mark M Davis · Stanford University · U19 · FY2010 · AI
A Controlled Trial of Masks and Hand Hygiene for Reducing Influenza Transmission
$1,011,914Benjamin Cowling · University Of Hong Kong · U01 · FY2007 · CI
Experimental characterization of the dynamics of immune responses to influenza
$1,010,549Rafi Ahmed · Emory University · U19 · FY2017 · AI
Generation of Robust Resident Memory T cells in Barrier Tissues through Skin Vaccination
$1,010,181Thomas S. Kupper · Brigham And Women'S Hospital · R01 · FY2018 · AI
Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia
$1,009,268Victor Nizet · University Of California, San Diego · R01 · FY2024 · AI
A Novel Live Non-replicating Universal Vaccine for Influenza
$1,009,220Sally R. Sarawar · Biomedical Research Instit/ Southern, Ca · R01 · FY2014 · AI
VTEU: Phase I Clinical Trial of an Influenza Vaccine
$1,009,020Robert Mulligan · Emory University · N01 · FY2016 · AI
Targeting the NS1 Protein for the Development of Influenza Virus Antivirals
$1,008,663Robert M Krug · University Of Texas At Austin · U01 · FY2011 · AI
Experimental characterization of the dynamics of immune responses to influenza
$1,008,020Rafi Ahmed · Emory University · U19 · FY2015 · AI
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
$1,007,282Roy Curtiss · University Of Florida · R01 · FY2015 · AI
Modeling the ecology of tissue-resident T cells
$1,005,945Andrew Yates · Columbia University Health Sciences · U01 · FY2023 · AI
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$1,005,748Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity
$1,005,250Ann C Duerr · Fred Hutchinson Cancer Research Center · R01 · FY2009 · DE
CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients
$1,005,131Arthur P Bertolino · Cytoagents, Inc. · R44 · FY2025 · CA
Integrated System for Rapid Detection of Respiratory Pathogens
$1,004,556Michael J Lochhead · Mbio Diagnostics, Inc. · R01 · FY2012 · AI
AT191: An inhaled & precision RNA therapeutic with pan-variant SARS-CoV-2 efficacy
$1,004,473Ariel Weinberger · Autonomous Therapeutics, Inc. · R44 · FY2025 · AI
Protective Mechanisms Against Pandemic Respiratory Virus
$1,003,023Eugene C Butcher · Stanford University · U19 · FY2008 · AI
Vaccine and Treatment Evaluation Units
$1,002,259David Bernstein · Cincinnati Childrens Hosp Med Ctr · N01 · FY2012 · AI
Monitoring of disease-induced skin VOC patterns from handheld and wearable chemical sensors
$1,002,189Cristina Elizabeth Davis · University Of California At Davis · U01 · FY2023 · TR
Clinical Core
$1,001,600Cornelia L Dekker · Stanford University · U19 · FY2012 · AI
Vanderbilt Vaccine and Treatment Evaluation Unit
$1,001,368Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2025 · AI
Non-Viral Pandemic Influenza Vaccine Development
$1,001,081Gary Fujii · Molecular Express, Inc. · U01 · FY2008 · AI